{"organizations": [], "uuid": "070475faaee482a5bdb33bfb51405363632a6e7c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-inflarx-announces-first-patient-en/brief-inflarx-announces-first-patient-enrolled-in-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSFWN1QQ0V0", "country": "US", "domain_rank": 408, "title": "BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T16:47:00.000+02:00", "replies_count": 0, "uuid": "070475faaee482a5bdb33bfb51405363632a6e7c"}, "author": "", "url": "https://www.reuters.com/article/brief-inflarx-announces-first-patient-en/brief-inflarx-announces-first-patient-enrolled-in-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSFWN1QQ0V0", "ord_in_thread": 0, "title": "BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "hidradenitis suppurativa reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8, 2018 / 2:47 PM / in 11 minutes BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa Reuters Staff 1 Min Read March 8 (Reuters) - Inflarx Nv: * INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-08T16:47:00.000+02:00", "crawled": "2018-03-08T17:04:25.008+02:00", "highlightTitle": ""}